drugset / Trial / NCT06514157
Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.
NaSingle-groupOpen-labelTreatment
Summary
A phase I study to assess the PK, safety, and tolerability of budesonide and albuterol delivered from a single dose of BDA MDI administered by inhalation in healthy Chinese participants.
Timeline
- Start
- 2024-08-19
- Primary completion
- 2024-09-09
- Completion
- 2024-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 160 ug | Inhaled |
| Subject | Salbutamol | Unknown | 180 ug | Inhaled |
Indications
No indication recorded.